of myelodysplasia or secondary AML 5, 6 and consequently a shortened survival. 7 Indeed, the development of cytogenetic abnormalities and MDS following ABMT for lymphoma We undertook a retrospective review of all 76 patients with AML transplanted between August 1986 and appear to be related to exposure to alkylating agents during conventional-dose chemotherapy rather than the highMarch 1995 at our center. All patients received melphalan (140-160 mg/m 2 ), etoposide (60 mg/kg) and total dose regimen.
As induction and consolidation chemotherapy for AML body irradiation. All patients had bone marrow cytogenetic analysis at regular intervals following ABMT.
do not generally include alkylating agents, we were interested in determining the incidence and significance of new The primary study end point was the development of the new cytogenetic abnormalities. Secondary end isolated cytogenetic abnormalities after ABMT for AML. points were the development of myelodysplasia (MDS) or AML. Sixty-two of 77 patients were alive at least 6 months post transplant. Cytogenetic abnormalities
Patients and methods developed in 7/62 patients (11%) following ABMT. No patients demonstrated MDS or AML. At a median of
We evaluated all patients undergoing ABMT for AML at our center between 1986 and 1995 to determine the fre-30 months after development of the cytogenetic abnormality, only one patient developed features suggestive quency and clinical significance of new clonal karyotypic abnormalities following transplantation. Patients Ͻ61 years but not diagnostic of MDS. All seven patients remain alive and leukemia-free up to 70 months after detection of age with ECOG performance status Ͻ2 were candidates for ABMT. Patients with persistent cytogenetic abnormaliof the abnormal clone. There was no increased incidence of cytogenetic abnormalities developing in patients ties or morphologic evidence of myelodysplasia following induction therapy were not eligible for ABMT. Intensive receiving a purged autograft. New cytogenetic abnormalities are frequent following ABMT for AML but do therapy and autotransplantation were performed in first or subsequent remission or early relapse with a marrow autonot appear to predict development of myelodysplasia or acute myeloid leukemia. These abnormalities may relate graft collected in morphologic and cytogenetic remission. The intensive therapy regimen consisted of intravenous to use of total body radiation as part of the high-dose therapy.
melphalan (140-160 mg/m 2 ), etoposide (VP-16) (60 mg/kg) and total body irradiation (TBI). The etoposide was Keywords: bone marrow transplantation; cytogenetics; acute myeloid leukemia; myelodysplasia administered as an infusion over 5 h for patients with good cardiac function and over 32 h for patients with left ventricular ejection fraction Ͻ45%. Patients in first complete remission were given a single fraction of TBI at a median Clonal cytogenetic abnormalities occur in the bone marrow rate of 50 cGy/min (range 30-60) to a total dose of 500 cGy of 50-90% of patients with acute myeloid leukemia (AML) while those in other disease states received six fractions of at the time of diagnosis and are strongly implicated in its 200 cGy administered at the same rate (total dose 1200 pathogenesis.
1,2 Furthermore, recurrence of the initial cGy). Patients were assessed at 3-monthly intervals for the malignant cytogenetic clone in the marrow of patients after first 2 years following ABMT and at 6-monthly intervals conventional-dose induction chemotherapy is usually assothereafter. Follow-up studies included a complete physical ciated with morphologic relapse. 3, 4 examination, complete blood count and bone marrow aspirNew clonal cytogenetic abnormalities appearing after ation with cytogenetic analysis. Cytogenetic studies were conventional chemotherapy for lymphoma or other maligperformed according to standard methods with the karyonancies are generally felt to be associated with a high risk types described according to the international system for cytogenetic nomenclature (ISCN). 9 We defined new cytogenetic abnormalities following ABMT as persistent clonal low-up after ABMT for the entire cohort was 39 months. The median age for all patients was 37 years (range 17-61). Thirty-six patients were male (47%) and 40 were female (53%). The FAB subtype of the patient's leukemia fractionated TBI while the remainder received a single fraction. Twenty-nine patients (38%) relapsed at a median of at diagnosis was M1 in 13, M2 in 22, M3 in nine, M4 in 10, M5 in 14, M6 in three, and M7 in one (four 9 months following ABMT. In no patient, however, did cytogenetic abnormalities precede morphologic evidence of unclassified). The karyotype of the malignant clone at diagnosis was known in 47 (62%). Twenty-seven (36%) had a relapse. In the one patient who developed morphologic evidence of MDS (refractory anemia with excess blasts), a cytogenetic abnormality at diagnosis while 20 (26%) were cytogenetically normal. Induction therapy at diagnosis of complex cytogenetic abnormality was identified 9 months after the dysplasia was documented. AML comprised a cytosine arabinoside containing regimen with an anthracycline; 22% received thioguanine in Sixty-two of the 76 patients transplanted were alive 6 months or more post transplant and eligible for assessment addition. Forty-four patients (58%) underwent ABMT in first complete remission (CR1), 24 (32%) in CR2 and eight of development of cytogenetic abnormalities. Seven of 62 (11%) of patients developed clonal cytogenetic abnormali-(11%) with more advanced disease including third or later CR or early relapse. The median time from diagnosis to ties. The characteristics of these seven patients are summarized in Table 2 . Cytogenetic abnormalities developed at a transplantation was 9 months.
The autograft was cryopreserved in liquid nitrogen for a median of 19 months after ABMT (range 7-24 months) and 28 months after diagnosis (range 14-30 months). In median of 55 days (range 6-390) and thawed immediately prior to infusion. In six consecutive patients as part of a four patients, the karyotype at the time of initial diagnosis of AML was known: two patients were karyotypically norclinical study, the autograft was purged with 4-hydroperoxycyclophosphamide (4-HC). In all remaining patients mal at diagnosis while two patients had a t(15;17) translocation. In the remaining three, the karyotype at diagnosis the marrow was unpurged. No patient received peripheral blood progenitor cells.
was not known. The post-transplant abnormality affected Ͻ50% of cells in all patients. Three had a single structural Treatment-related mortality was the cause of death in 8/76 patients (11%). Median predicted event-free survival abnormality while four had a complex karyotype. Two of the seven patients received autografts purged with 4-HC for all patients transplanted was 24.2 months. The median survival was not reached with a median follow-up of 39 while the remainder received an unpurged autograft. Table 3 summarizes the characteristics of all patients months and the actuarial event-free survival rate at 3 years was 46% (95% CI 24-72). All patients received TBI as part with AML transplanted at our centre categorized according to whether an abnormal clone was detected post transplant. of their high-dose regimen. Thirty-two patients received There is a well established association between cyto- ABMT. 8 The risk of MDS in this setting has been reported Single  5  44  Fractionated  2  32 to be as high as 18% at 6 years with a median survival of only 4-9 months.
8,12-14
In contrast, we report that although the acquisition of As in our patients, outcome was comparable to patients who remained karyotypically normal after ABMT. In our new cytogenetic abnormalities is frequent (11%), it was not predictive of the development of AML and was associated series, the majority of patients received an unpurged autograft and new cytogenetic abnormalities were observed in with dysplastic changes in only one patient with a median follow-up of 30 months (range 16-75 months). Furtherrecipients of both purged and unpurged autografts, suggesting factors other than purging are responsible. We cannot more, the clinical course in this patient is dissimilar from that reported for MDS following ABMT; the patient is alive exclude the possibility that purging contributed to the development of the abnormal clone in two of the patients. with no evidence of AML or progression of MDS 18 months after development of the cytogenetic abnormality.
All of our patients received TBI as part of the high-dose therapy regimen. The total dose of radiation administered Cytogenetic information at diagnosis was available in four out of seven patients. In these four patients the cytodid not affect the development of cytogenetic abnormalities as we observed a similar incidence in patients exposed to genetic abnormalities were detected post transplant and were unrelated to the initial malignant clone. In the remaina single fraction of 500 cGy compared to those receiving fractionated TBI to a total dose of 1200 cGy. The abnoring three patients the karyotype at diagnosis was not known. In these three patients we cannot exclude the possimalities we report affect multiple chromosomes, are often complex and are consistent with radiation-induced dambility that the clonal abnormality detected post ABMT represents relapse of the initial malignant clone. Cytogenetic age. 16 Although other authors suggest a possible association with TBI, 14 ,17 prior alkylating agent therapy or bone maranalysis on bone marrow at the time of harvesting revealed a normal karyotype in all patients. It is unlikely, however, row purging in their patients makes assessment of the influence of TBI in these reports difficult to determine. To as these three patients have been followed for Ͼ29 months without evidence of overt morphologic relapse.
date, there have been no reports addressing the incidence of chromosomal abnormalities following ABMT for AML We attempted to evaluate factors predisposing to the development of cytogenetic abnormalities in patients folin patients not treated with TBI. Cytogenetic abnormalities have been detected with some frequency following allolowing ABMT for AML. This analysis was limited by the small number of cases. The initial induction and convengeneic bone marrow transplantation and appear to be more frequent in patients receiving T cell-depleted marrow or tional-dose consolidation chemotherapy given at the time of the original diagnosis is a potential cause. However, all who were conditioned with TBI. 16, 18, 19 Of interest, it has been proposed that following allogeneic transplantation, patients transplanted were induced with a cytosine arabinoside-containing regimen and an anthracycline (daunomycin TBI contributes significantly to the development of cytogenetic abnormalities. 16 We are currently evaluating or mitoxantrone) and 22% received thioguanine as part of the TAD regimen. No patient received an alkylating agent patients with lymphoma transplanted with the same intensive chemotherapy regimen which excludes TBI to deteror etoposide as part of primary therapy. Therapy-induced cytogenetic changes are not commonly associated with mine the incidence of cytogenetic abnormalities in this group. anthracyclines or cytosine arabinoside and there are no reports of new cytogenetic abnormalities among the few We suggest that the development of a clonal cytogenetic abnormality following ABMT for AML cannot be equated AML patients who are long-term survivors following conventional-dose therapy alone. 15 For these reasons, we with development of secondary MDS or AML and is most likely related to the use of TBI in the intensive therapy believe the primary therapy is unlikely to contribute to the development of these abnormalities.
regimen. These abnormalities remain stable or resolve in the majority of cases, despite long follow-up and do not It is also unlikely that the use of etoposide in the highdose regimen contributed to the development of the clonal confer an adverse prognosis. abnormalities observed. 11q or 21q abnormalities are reported in as many as 50% of etoposide induced-MDS or AML. 15 No patient in our series had abnormalities involv
